1.

Good continuum of HIV care in Belgium despite weaknesses in retention and linkage to care among migrants

2.

Good continuum of HIV care in Belgium despite weaknesses in retention and linkage to care among migrants

3.

Good continuum of HIV care in Belgium despite weaknesses in retention and linkage to care among migrants

4.

Good continuum of HIV care in Belgium despite weaknesses in retention and linkage to care among migrants

5.

Good continuum of HIV care in Belgium despite weaknesses in retention and linkage to care among migrants

6.

Good continuum of HIV care in Belgium despite weaknesses in retention and linkage to care among migrants

7.

Good continuum of HIV care in Belgium despite weaknesses in retention and linkage to care among migrants

1.

Long-term treatment with atazanavir (ATV) in real life in Belgium: a retrospective observational cohort of 2264 HIV patients.

2.

Long-term treatment with atazanavir (ATV) in real life in Belgium: a retrospective observational cohort of 2264 HIV patients.

3.

Long-term treatment with atazanavir (ATV) in real life in Belgium: a retrospective observational cohort of 2264 HIV patients.

4.

Long-term treatment with atazanavir (ATV) in real life in Belgium: a retrospective observational cohort of 2264 HIV patients.

5.

Long-term treatment with atazanavir (ATV) in real life in Belgium: a retrospective observational cohort of 2264 HIV patients.

6.

Long-term treatment with atazanavir (ATV) in real life in Belgium: a retrospective observational cohort of 2264 HIV patients.

7.

Long-term treatment with atazanavir (ATV) in real life in Belgium: a retrospective observational cohort of 2264 HIV patients.

1.

Belgian guidelines for non-occupational HIV post-exposure prophylaxis 2017.

2.

Belgian guidelines for non-occupational HIV post-exposure prophylaxis 2017.

3.

Belgian guidelines for non-occupational HIV post-exposure prophylaxis 2017.

4.

Belgian guidelines for non-occupational HIV post-exposure prophylaxis 2017.

5.

Belgian guidelines for non-occupational HIV post-exposure prophylaxis 2017.

6.

Belgian guidelines for non-occupational HIV post-exposure prophylaxis 2017.

7.

Belgian guidelines for non-occupational HIV post-exposure prophylaxis 2017.

1.

Efficacy, durability, and tolerability of bictegravir/emtricitabine/tenofovir alafenamide for the treatment of HIV in a real-world setting in Belgium.

2.

Efficacy, durability, and tolerability of bictegravir/emtricitabine/tenofovir alafenamide for the treatment of HIV in a real-world setting in Belgium.

3.

Efficacy, durability, and tolerability of bictegravir/emtricitabine/tenofovir alafenamide for the treatment of HIV in a real-world setting in Belgium.

4.

Efficacy, durability, and tolerability of bictegravir/emtricitabine/tenofovir alafenamide for the treatment of HIV in a real-world setting in Belgium.

5.

Efficacy, durability, and tolerability of bictegravir/emtricitabine/tenofovir alafenamide for the treatment of HIV in a real-world setting in Belgium.

6.

Efficacy, durability, and tolerability of bictegravir/emtricitabine/tenofovir alafenamide for the treatment of HIV in a real-world setting in Belgium.

7.

Efficacy, durability, and tolerability of bictegravir/emtricitabine/tenofovir alafenamide for the treatment of HIV in a real-world setting in Belgium.

1.

Dynamics of Weight Change After Initiation of Contemporaneous Antiretroviral Therapy in Treatment-Naive HIV-1 Infected Patients: Results From the Belgian HIV Cohort 2015-2021.

2.

Dynamics of Weight Change After Initiation of Contemporaneous Antiretroviral Therapy in Treatment-Naive HIV-1 Infected Patients: Results From the Belgian HIV Cohort 2015-2021.

3.

Dynamics of Weight Change After Initiation of Contemporaneous Antiretroviral Therapy in Treatment-Naive HIV-1 Infected Patients: Results From the Belgian HIV Cohort 2015-2021.

4.

Dynamics of Weight Change After Initiation of Contemporaneous Antiretroviral Therapy in Treatment-Naive HIV-1 Infected Patients: Results From the Belgian HIV Cohort 2015-2021.

5.

Dynamics of Weight Change After Initiation of Contemporaneous Antiretroviral Therapy in Treatment-Naive HIV-1 Infected Patients: Results From the Belgian HIV Cohort 2015-2021.

6.

Dynamics of Weight Change After Initiation of Contemporaneous Antiretroviral Therapy in Treatment-Naive HIV-1 Infected Patients: Results From the Belgian HIV Cohort 2015-2021.

7.

Dynamics of Weight Change After Initiation of Contemporaneous Antiretroviral Therapy in Treatment-Naive HIV-1 Infected Patients: Results From the Belgian HIV Cohort 2015-2021.